A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
The user had two FUT hair transplants with 4,600 grafts for increased density, costing about $11,000 each, and has been using oral minoxidil and finasteride for over five years without side effects. The results are natural-looking with no visible scarring, and the user finds the procedure valuable despite the cost.
A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.
A 19-year-old male with a family history of balding is using finasteride to thicken his hair and is considering whether to add minoxidil. Users suggest continuing finasteride for several months before deciding on minoxidil.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
A user's 18-month progress on their hair loss treatment regimen, which includes 5mg oral minoxidil, 1.5mm microneedling with a pen once weekly, and 0.5mg/day dutasteride; other users noted the positive effects of finasteride and dutasteride in reducing DHT levels.
The user has been on finasteride for 18 months and added dutasteride after the first 6 months, with no hair regrowth observed. Bloodwork shows normal levels of DHT despite the use of both medications.
A user shared their hair loss journey, detailing their use of Kirkland Minoxidil 5%, finasteride, dutasteride, and weekly dermarolling. They experienced initial success with minoxidil but faced setbacks with oral minoxidil and are now back on topical treatments.
A transwoman shared her 11-month progress using hormone replacement therapy (HRT), finasteride, and minoxidil, reporting significant hair regrowth and satisfaction with the results. The discussion included various perspectives on HRT, its effects on hair and sexual function, and personal experiences with similar treatments.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.
Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.
The user has seen significant hair regrowth using a routine of minoxidil, finasteride, microneedling, scalp massage, and Nizoral. They are considering adding red light therapy and PRP to their regimen.
The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.
The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.
A 17-year-old is using topical finasteride and minoxidil for hair regrowth. The effectiveness of these treatments is discussed, with some users noting progress and others suggesting more time is needed for significant results.
Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.
A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Some individuals experience hair loss despite using treatments like 2.5 mg dutasteride, finasteride, and minoxidil, suggesting sensitivity to DHT or other factors. Various treatments and lifestyle changes are discussed, but results vary, and some consider hair transplants or other solutions.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
An 18-year-old shares progress in hair regrowth after 1.5 months using a topical treatment with finasteride, ketoconazole, minoxidil, and biotin. They report significant hairline improvement and a decrease in sex drive as a side effect.
The user reports positive progress in hair regrowth using 1mg oral finasteride, 3mg oral minoxidil, biotin, vitamin D, red light therapy, and microneedling. They note thickening at the hairline and some regrowth at the temples.